DALLAS, July 29, 2019 – Professor Chris Semsarian, Ph.D., M.P.H., FAHA, has been selected as the new editor-in-chief of Circulation: Genomic and Precision Medicine, one of 12 scientific journals of the American Heart Association, the world’s leading voluntary health organization devoted to fighting cardiovascular disease.
Circulation: Genomic and Precision Medicine, launched in 2008, aims to drive the future of cardiovascular diagnosis and disease management through investigations of clinical genetics and the novel application of precision medicine. The field of cardiovascular genomics and precision medicine entails diagnosing, treating and preventing inherited heart diseases by considering genetic make-up, the environment and lifestyle factors for each patient.
“I’m excited to take on the editorship of the leading cardiovascular genomics journal in the world, at a time when there are phenomenal advances in genomics and precision medicine approaches,” Semsarian said. “My vision is for the journal to be the ’go-to‘ journal for the latest, state-of-the-art research studies in the field of cardiovascular genomics and precision medicine, with an expanding readership to encompass more general cardiologists, geneticists and other allied health professionals.”
Semsarian is the Director of the Genetic Heart Disease and Hypertrophic Cardiomyopathy Clinic at Royal Prince Alfred Hospital in Sydney, director of the Australian Genetic Heart Disease Registry and a professor of medicine at the University of Sydney. In 2017, he was recognized as a Member in the General Division of the Order of Australia for significant service to medicine in the field of cardiology as a clinician and educator and for contributions to the community.
Prior to becoming editor-in-chief, Semsarian served as senior guest editor for the journal. He has published over 250 scientific publications in many of the highest-ranking cardiovascular and general medical journals and has authored best practice guidelines for inherited heart diseases.
“The American Heart Association’s Scientific Publishing Committee is pleased to announce that Dr. Chris Semsarian, an internationally renowned cardiologist and scientist studying genetic heart disease, has assumed responsibilities as editor-in-chief of Circulation: Genomic and Precision Medicine, effective July 2019,” said Mark Estes, M.D., the Scientific Publishing Committee chair and a professor of medicine at the New England Cardiac Arrhythmia Center at Tufts University School of Medicine in Boston. “The committee looks forward to working with Dr. Semsarian to ensure continued progress in publishing the best cardiovascular science in Circulation: Genomic and Precision Medicine.”
“As the new editor-in-chief, I hope to provide the international cardiovascular community with the absolute latest advances in genomics and precision medicine, with the ultimate goal to improve the care of our patients and their families with inherited heart diseases,” Semsarian said. “I also want to ensure the journal is inclusive, with goals to ensure equal representation of women as associate and assistant editors and on the editorial board.”
Semsarian plans to initiate many new features including state-of-the-art contemporary reviews, increased prominence of guideline documents, clinical case reports, introduction of visual abstracts and a greater interaction on social media, including Twitter-based “tweetorials” and journal clubs. You can follow Semsarian on Twitter at: @CSHeartResearch
Follow Circulation: Genomic and Precision Medicine, at:
- Twitter: @Circ_Gen https://twitter.com/circ_gen
- Facebook: @Circ_Gen https://www.facebook.com/CircGen/
- Circ Gen Podcast: https://www.ahajournals.org/circgen/podcast-archive
- Follow AHA/ASA news on Twitter @HeartNews
The American Heart Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at https://www.heart.org/en/about-us/aha-financial-information.
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173
Paige Ward: 214-706-1199; email@example.com
For Public Inquiries: 1-800-AHA-USA1 (242-8721)